Assess whether pediatric studies are necessary or waivable (001865)

Situation

The CMC and Development Pathways desk packet is biosimilar analytical similarity report after an inspector asking for batch records you cannot produce this week. CMC change-control owner in a rare-disease team designing a pediatric plan must name Pediatric studies are necessary or Waivable for this Pharma & Life Sciences file. CMC change-control owner in a rare-disease team designing a pediatric plan has to name Pediatric studies are necessary or Waivable for this Pharma & Life Sciences CMC and Development Pathways file.

Decision

CMC change-control owner in a rare-disease team designing a pediatric plan must choose Pediatric studies are necessary / Waivable using biosimilar analytical similarity report after an inspector asking for batch records you cannot produce this week.

Hypotheses to test

• An inspector asking for batch records you cannot produce this week is noise around an already-controlled CMC and Development Pathways process in a rare-disease team designing a pediatric plan, given biosimilar analytical similarity report.
• An inspector asking for batch records you cannot produce this week is the event in biosimilar analytical similarity report that forces Pediatric studies are necessary for CMC change-control owner under Pharma & Life Sciences.
• Biosimilar analytical similarity report shows a one-file miss after an inspector asking for batch records you cannot produce this week, not a CMC and Development Pathways program failure.
• Biosimilar analytical similarity report cannot decide pediatric studies are necessary yet after an inspector asking for batch records you cannot produce this week; hold is the only Pharma & Life Sciences close a rare-disease team designing a pediatric plan can defend.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in biosimilar analytical similarity report after an inspector asking for batch records you cannot produce this week.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on pediatric studies are necessary.
• For this Pharma & Life Sciences CMC and Development Pathways file, read biosimilar analytical similarity report against an inspector asking for batch records you cannot produce this week and write the one fact that would move pediatric studies are necessary for CMC change-control owner.